Savara Inc. Aktie
4,86 €
Deine Einschätzung
Savara Inc. Aktie
Was spricht für und gegen Savara Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Savara Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Savara Inc. | 0,84 % | 9,95 % | 8,00 % | 184,21 % | 13,55 % | 247,14 % | -41,48 % |
Gritstone Oncology Inc | 2,14 % | -20,03 % | -67,79 % | -73,01 % | -62,30 % | -90,29 % | - |
Innoviva Inc. | 0,74 % | 0,73 % | 1,47 % | 25,45 % | -5,48 % | 40,10 % | - |
Pacira Pharmaceuticals | -0,80 % | -2,34 % | -5,30 % | -35,57 % | -16,11 % | -52,38 % | -20,94 % |
Kommentare
News
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On March 21
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending